Dr. Craig Reynolds, M.D.
What this data tells you about Dr. Reynolds
Dr. Craig Reynolds is a hematology in Ocala, FL, with 20 years in practice. Based on federal Medicare data, Dr. Reynolds performed 81,784 Medicare services across 2,615 unique beneficiaries.
Between the years covered by Open Payments, Dr. Reynolds received a total of $54,145 from 69 pharmaceutical and/or device companies across 499 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology. The majority of payments are for speaking programs and promotional activities, reflecting participation in industry-sponsored events. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Reynolds is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
Medicare Practice Summary
Medicare Utilization ↗Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Iron infusion (Feraheme) | 46,410 | $0 | $4 |
| Denosumab injection (Prolia/Xgeva) | 13,800 | $18 | $51 |
| Anti-nausea injection (aprepitant) | 5,330 | $1 | $5 |
| Immune globulin infusion (Gammagard) | 4,272 | $36 | $108 |
| Epoetin alfa injection (Procrit) for anemia | 3,080 | $6 | $23 |
| Blood draw (venipuncture) | 1,422 | $8 | $9 |
| Complete blood count (CBC) with differential | 1,362 | $8 | $29 |
| Dexamethasone injection (steroid) | 1,209 | $0 | $3 |
| Office visit, established patient (20-29 min) | 678 | $65 | $239 |
| Anti-nausea injection (Aloxi/palonosetron) | 670 | $1 | $28 |
| Drug injection, under skin or into muscle | 595 | $10 | $69 |
| Office visit, established patient (30-39 min) | 540 | $95 | $339 |
| Anti-nausea injection (ondansetron/Zofran) | 384 | $0 | $9 |
| Injection of additional new drug or substance into vein | 366 | $12 | $61 |
| Administration of chemotherapy into vein, 1 hour or less | 238 | $97 | $378 |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 227 | $1 | $6 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 222 | $46 | $189 |
| Injection, diphenhydramine hcl, up to 50 mg | 121 | $1 | $3 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 100 | $15 | $56 |
| Injection of drug or substance into vein | 76 | $27 | $156 |
| Injection, methylprednisolone sodium succinate, up to 40 mg | 75 | $3 | $11 |
| Administration of chemotherapy into vein, each additional hour | 71 | $21 | $79 |
| New patient office visit (30-44 min) | 62 | $83 | $298 |
| Hospital follow-up visit, low complexity | 52 | $40 | $109 |
| Administration of additional new drug or substance into vein, 1 hour or less | 51 | $49 | $178 |
| Initial hospital admission, high complexity | 49 | $135 | $556 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 46 | $22 | $84 |
| Infusion, normal saline solution , 1000 cc | 46 | $2 | $7 |
| Office visit, established patient, complex (40-54 min) | 42 | $140 | $474 |
| Infusion into a vein for hydration, each additional hour | 37 | $10 | $42 |
| Automated urinalysis | 34 | $2 | $8 |
| Hospital follow-up visit, moderate complexity | 32 | $60 | $197 |
| Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional | 29 | $14 | $59 |
| Initial hospital admission, moderate complexity | 23 | $103 | $377 |
| Red blood count, automated test | 18 | $4 | $10 |
| New patient office visit, complex (60-74 min) | 15 | $173 | $585 |
Industry Payment Transparency
Open Payments through 2024 ↗Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
Payments by company (2024)
Associated products mentioned in payments ›
The majority of payments (57%) are for speaking programs and promotional activities, which reflect participation in industry-sponsored educational or marketing events. This is common in hematology and does not inherently indicate bias, but patients may wish to be aware.
Geographic Context
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Reynolds is a mixed practice specialist, with moderate Medicare volume, and high industry engagement (speaking/promotional, top 11%), with 20 years of practice experience.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Reynolds experienced with iron infusion (feraheme)?
Does Dr. Reynolds receive payments from pharmaceutical companies?
How do Dr. Reynolds's costs compare to other hematologys in Ocala?
What does Data Coverage mean?
Is this data up to date?
Explore related providers
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology